Thus, drugs targeting the CCL5–CCR5 axis are worthy of further study, considering that the functions of this signaling pathway are well established in the pathogenesis of breast cancer, GBM, and gastric cancer.490, 491, 492. This evidence concerns the gene CCL5 and breast carcinoma.